Fratino, Lucia
Polesel, Jerry
Giunta, Emilio Francesco
Maruzzo, Marco
Buti, Sebastiano
Hassan, Mona Ali
Basso, Umberto
Rebuzzi, Sara Elena
De Giorgi, Ugo
Cinausero, Marika
Lipari, Helga
Gamba, Teresa
Bimbatti, Davide
Dri, Arianna
Ermacora, Paola
Vignani, Francesca
Fornarini, Giuseppe
Rescigno, Pasquale
Banna, Giuseppe Luigi
Funding for this research was provided by:
Italian Ministry of Health
Prostate Cancer Foundation YI award
FPRC 5 PER MILLE – Ministero della Salute 2017 – PTCRC SEE PROS ONCOLOGIA
Italian Ministry of Health, Ricerca Corrente 2022
Article History
Received: 4 July 2023
Accepted: 2 February 2024
First Online: 28 February 2024
Competing interests
: E.F.G. received personal fees from Novartis and travel accommodation from Janssen. U.D.G. received honoraria for advisory boards or speaker fees for Pfizer, BMS, MSD, PharmaMar, Astellas, Bayer, Ipsen, Roche, Novartis, Clovis, GSK, AstraZeneca, institutional research grants from AstraZeneca, Sanofi and Roche. S.E.R. received honoraria as a speaker at scientific events and travel accommodation from Amgen, GSK, BMS, MSD. D.B. received personal fees for Talks or Advisory/Consultant Roles from Ipsen, Astellas, Janssen, Novartis, BMS, MSD outside the submitted work. G.F. served as an advisory board member for Astellas, Janssen, Pfizer, Bayer, MSD, Merck and received travel accommodation from Astellas, Janssen, Bayer. G.L.B. reported personal fees from Astellas and AstraZeneca. P.R. has served as a consultant/advisory board member for MSD and Astra Zeneca. The other authors declare that they have no conflict of interest.